Search

Your search keyword '"Triplett, Todd A."' showing total 96 results

Search Constraints

Start Over You searched for: Author "Triplett, Todd A." Remove constraint Author: "Triplett, Todd A."
96 results on '"Triplett, Todd A."'

Search Results

1. IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition

2. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study

3. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.

5. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

7. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

8. SARS-CoV-2 Humoral Immune Responses in Convalescent Individuals Over 12 Months Reveal Severity-Dependent Antibody Dynamics

9. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy

11. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.

12. Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

13. Supplementary Data from Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy

14. Data from Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy

16. Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy

17. Abstract 1298: An allosteric SHP2 inhibitor RMC-4550 induces immunogenicity in pancreatic adenocarcinoma (PDA) and enhances the cytotoxicity of CD8+ effector T cells

18. Abstract 4109: Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer in part by activating lysosome biogenesis and autophagy via TFEB and TFE3

20. Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.

22. Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.

25. Tumor-associated myeloid cells provide critical support for T-ALL

27. Comprehensive and Integrated Genomic Characterization of Human Immunome in Cancer

28. Tumor-associated myeloid cells provide critical support for T-ALL in vivo

30. The Force Awakens: Illuminating the Role of Kynurenine in Cancer Progression and Treatment

31. Microglia depletion and alcohol: Transcriptome and behavioral profiles

36. Microglia depletion and alcohol: Transcriptome and behavioral profiles.

38. The Force Awakens: Illuminating the role of kynurenine in cancer progression and treatment.

Catalog

Books, media, physical & digital resources